INCYIncyte CorporationNot started yet
A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma With FGFR2 Fusion or Rearrangements After at Least 1 Prior Line of Systemic Therapy
Unresectable Cholangiocarcinoma · Advanced/Metastatic Cholangiocarcinoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 72 (planned)
- Started
- Dec 15, 2026
- Main results expected
- Feb 25, 2031
- Fully finished
- Mar 27, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Objective Response
Measured over: Up to approximately 18 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07862998 · record last updated 2026-10-20 · checked 2026-11-09 15:47 UTC